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University, Uppsala, SwedenObjective: To determine expression of stanniocalcin-1 (STC1) in human endometrium with and without endometriosis and its
regulation by steroid hormones.
Design: Laboratory study.
Setting: University.
Patient(s): Nineteen women with endometriosis and 33 control women.
Intervention(s): Endometrial biopsy and fluid sampling.
Main OutcomeMeasure(s): Analysis of early secretory (ESE) and midsecretory (MSE) endometrial secretomes from fertile women with
the use of nano–liquid chromatography–dual mass spectrometry; real-time quantitative polymerase chain reaction, and
immunohistochemistry for STC1 and its receptor calcium-sensing receptor (CASR) mRNA and proteins in endometrium with and
without endometriosis; evaluation of STC1 and CASR mRNA expression in endometrial stromal fibroblasts (eSF) from women with
and without endometriosis decidualized with the use of E2P or 8-bromo-cyclic adenosine monophosphate (cAMP).
Result(s): STC1 protein was strongly up-regulated in MSE versus ESE in endometrial fluid of fertile women. STC1 mRNA significantly
increased in MSE from women with, but not from those without, endometriosis, compared with proliferative endometrium or ESE, with
no significant difference throughout the menstrual cycle between groups. STC1 mRNA in eSF from control women increased>230-fold
on decidualization with the use of cAMP versus 45-fold from women with endometriosis, which was not seen on decidualization with
E2/P. CASR mRNA did not exhibit significant differences in any condition and was not expressed in isolated eSF. STC1 protein
immunoexpression in eSF was significantly lower in women with endometriosis compared with control women.
Conclusion(s): STC1 protein is significantly up-regulated in MSE endometrial fluid and is dysregulated in eutopic endometrial tissue
from women with endometriosis. It is likely regulated by cAMP and may be involved in the pathogenesis of decidualization defects.
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VOL. 106 NO. 3 / SEPTEMBER 1, 2016H uman endometrium is a dy-namic tissue that undergoes cy-clic morphologic andmolecular
changes under a changing hormonal
milieu and plays a central role in human
implantation. Endometrial tissue in hu-
mans and other mammals is a target of
extensive research with the goal of
increasing understanding of its physi-
ology and pathophysiology and
improving treatment of gynecologic
pathologies such as endometriosis,681
ORIGINAL ARTICLE: ENDOMETRIOSISadenomyosis, recurrent pregnancy loss, as well as implanta-
tion failure and unexplained infertility.
High-throughput ‘‘omics’’ studies of global gene expres-
sion profiling in human endometrium have identified
stanniocalcin-1 (STC1) as an important player in normal
and diseased endometrial functions. STC is expressed in
pre-pregnancy endometrium and early pregnancy decidua
in rats and pigs, is regulated by estrogen and progesterone,
and has been suggested as an implantation marker in pig
endometrium (1, 2). In humans, consistent midsecretory
endometrial (MSE) STC1 gene expression was demonstrated
in patients who conceived with the help of assisted
reproductive technologies (3). STC1 was significantly up-
regulated in microarray analysis of MSE of the normal men-
strual cycle compared with early secretory endometrium (ESE)
(4), and was down-regulated in microarray analysis of MSE
from women with unexplained infertility versus fertile con-
trol women (5), suggesting a possible role in human endome-
trial receptivity and implantation. Placental expression of
STC1 was documented in a well designed microarray study
of women with pregnancy complications, which demon-
strated increased STC1 in placenta and serum at term in
women with pregnancy complications, particularly pre-
eclampsia and small-for-gestational-age babies (6).
STC1 is a glycoprotein phosphorylated by protein kinase
C (7), initially described in a bony fish, and produced by
unique endocrine glands, the corpuscles of Stannius, eliciting
antihypercalcemic and antihypophosphatemic responses in
various tissues (8, 9). In mammals, STC1 is expressed in a
wide variety of tissues, and interestingly is not detected in
the circulation under normal conditions except during
pregnancy (9–11), suggesting an autocrine/paracrine rather
than an endocrine function. STC1 in mammals is not
necessarily directly linked to calcium/phosphorus pathways,
but rather is regulated by multiple factors (9). Its roles in
calcium homeostasis, bone, and muscle formation,
angiogenesis, and reproduction were demonstrated in
experiments with transgenic mice that experienced growth
retardation and small litter size (11, 12).
The STC receptor, calcium-sensing receptor (CASR), is a
G-protein–coupled receptor initially identified in bovine
parathyroid cells and expressed in wide variety of tissues,
including ovaries and uterus in human and rodents (13–15).
Its major physiologic role is thought to be maintenance of
calcium homeostasis, including regulation of secretion,
gene expression, cell proliferation, differentiation, and
apoptosis (13, 16). CASR was found to mediate STC1
secretion in response to extracellular calcium fluctuation in
fish (17). It is expressed in first-trimester and term human
placenta (18, 19) and is induced during implantation and
decidualization in rat uterus (15).
Based on the above, there are limited data on human
endometrial STC1 expression, regulation, and signaling
through its receptor. We therefore aimed to investigate
expression of STC1 and its receptor in human endometrium
and regulation of STC1 in human endometrial stromal fibro-
blasts (eSF) in women without and with endometriosis in an
effort to determine potential roles for this protein/receptor
complex in normal and abnormal endometrial function.682MATERIALS AND METHODS
Study Subjects and Materials
Endometrial samples were obtained through the University of
California–San Francisco (UCSF) National Institutes of Health
Human Endometrial Tissue and DNA Bank and from healthy
volunteers at the Department of Obstetrics and Gynecology,
Karolinska University Hospital, Huddinge, Sweden, and Tartu
University Women's Clinic, Tartu, Estonia, with appropriate
Institutional ReviewBoard (UCSF) and Ethics Committee (Kar-
olinska Institute and University of Tartu) approvals. Written
informed consents were obtained from all participating sub-
jects. Table 1 summarizes characteristics of all participating
women and the techniques applied for analyzing the samples.
Endometrial secretome samples for proteomics analysis
were collected from early secretory (ESE, LHþ2) and midse-
cretory (MSE, LHþ8) phase endometria during the same men-
strual cycle from fertile healthy volunteers (n ¼ 6; age 31 
1.5 y). The day of the LH surge (LHþ0) was determined with
a urinary ovulation prediction test (Kaigert), which is an
accepted and validated method for predicting ovulation in
the clinical and translational research setting; it is also patient
friendly, because it is a noninvasive test applicable for self-
use at home. However, being aware of substantial interpatient
variability, we supported our endometrial dating with endo-
metrial histology. Histology samples were collected for
confirmation of endometrial dating according to the criteria
of Noyes et al. (20) and were found to correspond to days
19–24 of the 28-day cycle.
Endometrial biopsies for polymerase chain reaction
(PCR), immunohistochemistry (IHC), and cell culture experi-
ments were obtained from subjects with and without endome-
triosis (n ¼ 19 and n ¼ 27, respectively). Menstrual cycle
phase was assigned by the day of LH surge and endometrial
histology as above. In addition, all samples used for mRNA
expression analysis were assigned cycle phase by means of
bioinformatics methods (21). Only samples where all evalua-
tion criteria were in agreement were used in the study.
Control subjects (no endometriosis) were healthy women
35.6 0.86 years of age (range 23–49 y) undergoing gyneco-
logic surgery for pelvic pain (with no endometriosis found
during laparoscopy) or management of fibroids, healthy vol-
unteers without uterine pathology, or women undergoing
laparoscopic tubal ligation. Control subjects had regular men-
strual cycles, were not pregnant, had no history of endometri-
osis, and had not been on hormonal treatment for at least
3 months before tissue sampling.
Women with endometriosis participating in the study
were 35.9 1.65 years of age (range 22–49 y), were not preg-
nant, and did not use any hormonal medication for at least
3 months before surgery. The diagnosis of endometriosis
was based on visualization of lesions during laparoscopy
and confirmed by histology. Staging of endometriosis was
defined according to the revised American Fertility Society
classification system (22).
Out of 19 samples from women with endometriosis and
27 samples from control women (without endometriosis), 14
and 10 whole tissue samples, respectively, were used for
real-time quantitative reverse-transcription (RT) PCR (n ¼ 6VOL. 106 NO. 3 / SEPTEMBER 1, 2016
TABLE 1
Characteristics of patients who donated endometrial biopsy or fluid samples for the study.
Patient Cycle phase Type of experiment Diagnosis at laparoscopy Age, y Ethnicity
Endometriosis
233 MSE Cell culture and decidualization,
qPCR
Mild endometriosis, pelvic pain 31 White
243 ESE Cell culture and decidualization,
qPCR
Minimal endometriosis, bilateral
ovarian cyst, intramural myoma
46 White
267 LSE Cell culture and decidualization,
qPCR
Mild endometriosis, pelvic pain 32 White
268 Not Evaluated Cell culture and decidualization,
qPCR
Mild endometriosis, intramural
myoma
38 Asian
288 PE Cell culture and decidualization,
qPCR
Severe endometriosis 22 White
270 PE Cell culture and decidualization,
qPCR
Mild endometriosis 49 White
651 PE Tissue qPCR Severe endometriosis/
endometrioma, chronic pelvic
pain, fibroid uterus
37 White
575 PE Tissue qPCR Severe endometriosis/
endometrioma, chronic pelvic
pain
26 Unknown
587 PE Tissue qPCR Severe peritoneal, rectovaginal
endometriosis, chronic pelvic
pain
36 White
ST90 PE Tissue qPCR Severe pelvic endometriosis, chronic
pelvic pain
42 White
607 ESE Tissue qPCR Severe peritoneal and rectovaginal
endometriosis, chronic pelvic
pain
24 Asian
517 ESE Tissue qPCR Severe peritoneal endometriosis,
chronic pelvic pain, fibroids,
infertility
35 Unknown
ST112 ESE Tissue qPCR Severe peritoneal endometriosis,
chronic pelvic pain
38 White
645 MSE Tissue qPCR Severe peritoneal endometriosis,
chronic pelvic pain
39 Asian Indian
678 MSE Tissue qPCR,
immunohistochemistry
Severe endometriosis, fibroid
uterus, chronic pelvic pain
44 White
ST96 MSE Tissue qPCR Severe peritoneal endometriosis,
chronic pelvic pain
31 White
635 MSE Immunohistochemistry Mild endometriosis, bleeding,
intramural myoma
42 White
516 MSE Immunohistochemistry Severe endometriosis, intramural
myoma
34 Asian
540 MSE Immunohistochemistry Severe rectovaginal endometriosis 37 White
No endometriosis
229 LSE Cell culture and decidualization,
qPCR
Pelvic pain (no endometriosis at
laparoscopy)
47 White
236 PE Cell culture and decidualization,
qPCR
Symptomatic pelvic prolapse 47 White
237 ESE Cell culture and decidualization,
qPCR
Intramural myoma, left paratubal
cyst
39 White
238 ESE Cell culture and decidualization,
qPCR
Endometrial polyp 41 Black
285 PE Cell culture and decidualization,
qPCR
Intramural myoma, pelvic adhesions 37 White
293 PE Cell culture and decidualization,
qPCR
Intramural myoma 49 White
310 PE Cell culture and decidualization,
qPCR
Intramural myoma, enterocele 41 Asian
ME 09 PE Tissue qPCR Undesired fertility 37 White
M182 PE Tissue qPCR Healthy volunteer 34 White
M169 PE Tissue qPCR Healthy volunteer 32 White
ETB038 PE Tissue qPCR Egg donor, natural cycle biopsy 23 White
ETB048 PE Tissue qPCR Egg donor, natural cycle biopsy 28 Black
ETB065 PE Tissue qPCR Egg donor, natural cycle biopsy 29 White
ME34 ESE Tissue qPCR Undesired fertility 33 White
ME13 ESE Tissue qPCR Pelvic pain (no endometriosis at
laparoscopy)
33 Black
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TABLE 1
Continued.
Patient Cycle phase Type of experiment Diagnosis at laparoscopy Age, y Ethnicity
ME42 ESE Tissue qPCR Undesired fertility 37 White
ME36 MSE Tissue qPCR Undesired fertility 35 Black
ME50 MSE Tissue qPCR Undesired fertility 35 White
16 MSE Tissue qPCR Healthy fertile volunteer 42 Unknown
22 MSE Tissue qPCR Healthy fertile volunteer 40 Unknown
30 MSE Tissue qPCR Healthy fertile volunteer 35 Unknown
MM1 MSE Immunohistochemistry Healthy fertile volunteer 36 White
MM2 MSE Immunohistochemistry Healthy fertile volunteer 41 White
MM5 MSE Immunohistochemistry Healthy fertile volunteer 30 White
MM16 MSE Immunohistochemistry Healthy fertile volunteer 35 White
ST18 MSE Immunohistochemistry Healthy fertile volunteer 37 White
ST21 MSE Immunohistochemistry Healthy fertile volunteer 35 White
Secr1 ESE, MSE Mass spectrometry, histology Healthy fertile volunteer 30 White
Secr2 ESE, MSE Mass spectrometry, histology Healthy fertile volunteer 32 White
Secr3 ESE, MSE Mass spectrometry, histology Healthy fertile volunteer 32 White
Secr4 ESE, MSE Mass spectrometry, histology Healthy fertile volunteer 33 White
Secr5 ESE, MSE Mass spectrometry, histology Healthy fertile volunteer 30 White
Secr6 ESE, MSE Mass spectrometry, histology Healthy fertile volunteer 29 White
Note: ESE ¼ early secretory phase endometrium; LSE ¼ late secretory phase endometrium; MSE ¼ midsecretory phase endometrium; qPCR ¼ quantitative polymerase chain reaction; PE ¼ pro-
liferative phase endometrium.
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without endometriosis, respectively; n ¼ 3 in ESE in each
group; and n ¼ 5 and n ¼ 3 in MSE from women with and
without endometriosis, respectively). IHC was performed on
MSE samples: n¼ 4 and n¼ 6 for endometriosis and no endo-
metriosis groups, respectively.
Isolated eSF from women with (n ¼ 6) and without endo-
metriosis (n¼ 7) were used in cell culture experiments (as shown
previously, cycle phase does not confound response [23]).
Early Secretory and Midsecretory Phase
Endometrial Fluid Proteomics Analysis
The secretomes were obtained by uterine flushing, i.e., inject-
ing 0.5 mL of phosphate-buffered saline solution (PBS) into
the uterine cavity, followed by aspiration of the fluid. Before
protein extraction, the samples were precleared with centrifu-
gation at 450g for 5 minutes. The collected secretomes were
separated into six fractions according to molecular weight
with the use of sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (Invitrogen–Thermo Fisher Scientific). Pro-
teins were reduced, alkylated, and in-gel digested with the
use of dimethylated porcine trypsin (Sigma) followed by anal-
ysis with nano–liquid chromatography–dual mass spectrom-
etry (Dionex Ultimate 3000 RSLC and Q Exactive MS/MS;
Thermo Fisher Scientific). The label-free peptide elution pro-
files of different study subjects were identified and quantified
with the use of the Maxquant software package (UniprotKB
human reference proteome database, September 2014
version) (24). Label-free data were normalized with the use
of the MaxLFQ (25) algorithm and compared by means of
paired t test statistics.Total RNA Isolation and Real Time RT-PCR
Total RNA from endometrial biopsies and cells was purified
with the use of the Qiagen RNeasy Plus Mini kit according684to the manufacturer's instructions. Samples were stored in
RNase-free H2O and quantified by spectroscopy, and the pu-
rity was analyzed with the use of the 260/280 absorbance ra-
tio. RNA quality and integrity were analyzed with the use of
the Agilent Bioanalyzer 2100 with all samples having high-
quality RNA (RNA integrity number 9.7–10.0). For real-time
quantitative RT-PCR analysis, 1 mg RNA was converted to
cDNA with the use of the iScript cDNA Synthesis kit (Bio-
Rad Laboratories). Duplicate mRNAs were pooled from each
set of treatments. The real-time RT-PCR reaction was carried
out for 40 cycles with primers to insulin growth factor–bind-
ing protein 1 (IGFBP1) (eSF only), PRL (eSF only), STC1 (eSF
and tissue), and CASR (eSF and tissue). Relative gene expres-
sion was normalized with the use of RPL19 as the internal
reference, which has been shown to have reproducibility
and stable expression in endometrial tissue (23, 26). The
following primer sequences were used: IGFBP1: forward,
50-CTATGATGGCTCGAAGGCTC-30, reverse, 50-TTCTTGTTG
CAGTTTGGCAG-30; PRL: forward, 50-CATCAACAGCTGCCA
CACTT-30, reverse, 50-CGTTTGGTTTGCTCCTCAAT-30; STC1:
forward, 50-GCAGGAAGAGTGCTACAGCAAG-30, reverse,
50-CATTCCAGCAGGCTTCGGACAA-30; CASR: forward, 50-CT
CTTCACCAATGGCTCCTGT-30, reverse, 50-CCACACTCATCAA
AGGTCACCTG-30; and RPL19: forward, 50-GCAGATAATGGG
AGGAGCC-30, reverse, 50-GCCCATCTTTGATGAGCTTC-30.Immunohistochemistry
Paraffin-embedded sections (4 mm) of endometrial biopsies
were deparaffinized and washed. Antigen retrieval was per-
formed by submerging slides in citrate buffer (1 Citra
Plus; Vector Laboratories) at 90C for 10 minutes. Endoge-
nous peroxidase was blocked with the use of 3% H2O2 in
methanol for 10 minutes. Sections were then incubated with
10% blocking normal goat or horse serum in PBS (Vector Lab-
oratories) for 30 minutes for anti-STC1 (rabbit anti–humanVOL. 106 NO. 3 / SEPTEMBER 1, 2016
Fertility and Sterility®polyclonal; Santa Cruz Biotechnology) or anti-CASR (mouse
anti–human monoclonal; Abcam) antibodies, respectively.
Thereafter, STC1 and CASR primary antibodies were applied
at dilutions of 1:150 and 1:200, respectively, at 4C overnight.
Nonimmune IgG of equivalent concentration from the same
species was used as negative control.
The binding of primary antibodies was detected with the
use of secondary antibodies: goat antirabbit and horse anti-
mouse (Vector Laboratories) for 1 hour at room temperature,
at a 1:300 dilution for both. After 30minutes’ incubation with
ABC complex (Vectastain Elite ABC immunoperoxidase
detection kit; Vector Laboratories), diaminobenzidine–
hydrogen peroxide substrate (DAB kit; Vector Laboratories)
was added to the slides; slides were rinsed with distilled water,
counterstained with hematoxylin (Vector Laboratories), and
mounted with the use of mounting medium. A Leica micro-
scope was used to evaluate and photograph the slides.
Semiquantitative evaluation of IHC was performed by
two observers, blinded to the identity of the slides, using a
grading system; each sample was analyzed twice. Staining in-
tensity and the number of stained cells were graded on the
following numeric scale: 0 ¼ no staining;  ¼ few stained
cells; þ ¼ faint staining; þþ ¼ moderate staining; and
þþþ¼ strong staining. The average values from the two ob-
servers are presented.Endometrial Stromal Cell Isolation and Culture
Fresh endometrial tissue was digested with the use of collage-
nase as described previously (27). Human eSF were separated
from epithelium based on size and plated with the use of
DMEM/MCDB-105 medium containing 10% charcoal-
stripped fetal bovine serum (FBS), insulin (5 mg/mL), genta-
micin, penicillin, and streptomycin, as described previously
(23, 26). At passage 2, cells were cultured to near
confluence in the same medium, followed by changing to
low-serummedium (2% FBS) and cultured for 24 hours before
the onset of treatment. All cell culture experiments were con-
ducted with the use of 2nd to 4th cell passages; cell purity
(99% stromal fibroblasts) was determined by means of immu-
nostaining with cytokeratin, vimentin, and CD45 antibodies,
as described previously (23).Decidualization of Human Endometrial Stromal
Fibroblasts
Human eSF were treated with 0.5 mmol/L 8-bromo-cyclic
adenosine monophosphate (cAMP) for 96 hours or with E2
(10 nmol/L) alone or E2 (10 nmol/L) plus P (1 mmol/L) (E2/P)
for 14 days or vehicle. The duration and hormone concentra-
tions were optimized previously (23). 8-Bromo-cAMP and
steroid hormones were obtained from Sigma-Aldrich. All cul-
tures were performed in duplicate. Culture media were
changed every other day. Time ‘‘zero’’ (t ¼ 0) control subjects
were collected before initiation of treatment. Cells lysed in
RLT lysis buffer (Qiagen) containing 0.1% b-mercaptoethanol
and culture medium were collected after 96 hours of incuba-
tion (cAMP-treated samples) or 14 days (E2/P-treated
samples).VOL. 106 NO. 3 / SEPTEMBER 1, 2016Enzyme-linked Immunosorbent Assay
IGFBP1 and PRL proteins in the culture media were measured
to assess the decidualization status of eSF with the use of
ELISA, according to the manufacturers’ instructions (Alpha
Diagnostic International and Diagnostic Systems Labs,
respectively). All samples were assayed in duplicate. A stan-
dard curve was run in each experiment. Levels of IGFBP1
and PRL for each sample were normalized to total RNA. Inter-
and intra-assay coefficients of variation for the IGFBP1
ELISA were 5%–7.4% and 2.4%–3.4%, respectively, and for
PRL were 6.7%–10.4% and 7.8%–8.2%, respectively. Mini-
mum detection limits for PRL and IGFBP1 assays were
0.14 ng/mL and 0.4 ng/mL, respectively.Statistical Evaluation
Statistical analysis for the qunatitative RT-PCR and immuno-
histochemistry were performed with the use of the nonpara-
metric one-way analysis of variance Kruskal-Wallis test.
Results from the ELISA analysis demonstrated a normal dis-
tribution, and a two-tailed Student t test assuming unequal
variances was applied. Significance was determined at
P%.05.RESULTS
Stanniocalcin-1 Protein is Up-regulated in
Midsecretory Phase Endometrial Secretome
We identified STC1 protein with eight peptides (Supplemental
Table 1, available online at www.fertstert.org) in endometrial
aspirates from fertile women without endometriosis. With the
use of label-free proteomics data, we observed STC1 protein
to be significantly (P¼ .0004) up-regulated (mean fold change
þ39.6) in MSE (LHþ8) versus ESE (LHþ2) endometrial fluid
or secretome (Fig. 1A).Stanniocalcin-1 and CASR Expression in Human
Endometrial Tissue, mRNA, and Protein
In women without endometriosis, endometrial STC1 mRNA
expression fluctuated throughout the menstrual cycle; how-
ever, the differences did not reach statistical significance
(P¼ .088; Fig. 1B). In endometrium from women with endo-
metriosis, STC1 mRNA expression significantly increased in
MSE compared with PE or ESE (P¼ .043; Fig. 1B). However,
when comparing STC1 mRNA expression in nonendometrio-
sis and endometriosis samples, there was no statistically sig-
nificant difference throughout the menstrual cycle (P>.1;
Fig. 1C). On the other hand, STC1 receptor CASR mRNA did
not change significantly throughout the menstrual cycle in
both women with and without endometriosis (P>.1;
Fig. 1B), and there was no significant difference when its
expression was compared between subjects with versus
without endometriosis (P>.1; Fig. 1C).
Immunohistochemistry was used to evaluate the specific
cell-type expression of STC1 protein in midsecretory human
endometrium. We observed cytoplasmic STC1 protein expres-
sion in both epithelial and stromal cells from women with and
without endometriosis (Fig. 2A). STC1 immunoexpression in685
FIGURE 1
(A) Stanniocalcin-1 (STC1) protein level is increased in receptive (LHþ8) phase endometrial secretome. Paired data from six fertile women are
presented. X-axis values were obtained by taking log2 from summed peptide peak areas of STC1 protein in different samples. Paired t test
P¼.0004, with significance accepted at P%.05. (B) Relative expression of STC1 and calcium-sensing receptor (CASR) mRNA in human
endometrial tissue throughout the menstrual cycle in women with and without endometriosis. (C) Expression of STC1 and CASR mRNA in
human endometrial tissue throughout the menstrual cycle in women with endometriosis normalized to samples from women without
endometriosis and expressed as fold change. ESE ¼ early secretory phase endometrium; MSE ¼ midsecretory phase endometrium; PE ¼
proliferative phase endometrium. Nonparametric one-way analysis of variance Kruskal-Wallis test was used for statistical analysis, and
significance was accepted at P%.05.
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FIGURE 2
(A) Immunohistochemical evaluation of STC1 protein expression in midsecretory human endometrium from women without and with
endometriosis. LE ¼ luminal epithelium; GE ¼ glandular epithelium. *Statistically significant difference between LE and GE and between GE
and stroma: P<.02. #Statistically significant difference in stromal staining between no endometriosis and endometriosis samples: P¼.04.
Magnification 200. One-way Kruskal-Wallis test was used for statistical analysis, with significance accepted at P%.05. (B)
Immunohistochemical evaluation of CASR protein expression in mid-secretory human endometrium from women without and with
endometriosis. No stromal expression of CASR was observed, and no difference in epithelial (luminal and glandular) staining was noted
between specimens from women with versus without endometriosis. Magnification 200. Abbreviations as in Figure 1.
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ORIGINAL ARTICLE: ENDOMETRIOSISdisease-free women was significantly higher in luminal epithe-
lium and stroma compared with glandular epithelium (P< .02).
In endometriosis, there was no significant difference in STC1
protein expression in epithelial cells; however, its expression
in endometrial stromal cells was significantly decreased in
women with endometriosis compared with control women
(P¼ .04; Fig. 2A). When analyzing CASR protein immunoex-
pression, no stromal expression of CASR was observed, and it
had faint cytoplasmic expression in epithelial cells, both luminal
and glandular, whichwas not different between specimens from
women with versus without endometriosis (Fig. 2B).Stanniocalcin-1 and CASR Expression in Cultured
Human Endometrial Stromal Fibroblasts and
Effect of Decidualization Stimuli
Next, we investigated the expression of STC1 and CASR
mRNA in cultured eSF and their response to decidualizationFIGURE 3
Expression of STC1 mRNA in decidualized human endometrial stromal fib
(cAMP) for 96 hours, normalized to 96-hour control, or (B) 10 nmol/L
Kruskal-Wallis test was used for statistical analysis, with significance accep
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688stimuli in vitro. We subjected eSF to short-term decidualiza-
tion with the use of cAMP for 96 hours or long-term decidu-
alization with P (with estrogen priming) for 14 days, as
described in the Materials and Methods section. Decidualiza-
tion of eSF was assessed by means of IGFBP1 and PRL mRNA
and protein secretion (data not shown, but significance re-
ported earlier [23]).
STC1 mRNA expression was dramatically up-regulated
by >230-fold by cAMP in control women (P¼ .02 vs. vehicle
control) compared with 45-fold in women with endometriosis
(P¼ .001 vs. vehicle control). However, the difference in de-
gree of decidualization between samples from subjects with
versus without endometriosis did not reach statistical signif-
icance owing to large variability between samples (P¼ .15;
Fig. 3A). In contrast, there was no significant change in
STC1 mRNA in response to E2/P stimulus by eSF from women
without endometriosis, which did not differ significantly from
the response of eSF from women with endometriosis (P¼ .2;roblasts (eSF) with (A) 0.5 mmol/L cyclic adenosine monophosphate
E2/1 mmol/L P for 14 days, normalized to 14-day control. One-way
ted at P%.05. Abbreviations as in Figure 1.
VOL. 106 NO. 3 / SEPTEMBER 1, 2016
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ples analyzed in both groups.DISCUSSION
Endometrial STC1 is Dysregulated in
Endometriosis
We demonstrated that STC1 and CASR are expressed in hu-
man endometrial tissue. Despite STC1mRNA detection during
various microarray studies on human endometrium under
different conditions, there were no attempts to characterize
its expression in endometrial cell types and involvement in
the decidualization process until now. Yet the very robust
up-regulation of STC1 protein in endometrial fluid secretome
in the midsecretory versus early secretory phase of healthy
subjects reported here is potentially a clinically relevant
finding. Unfortunately, we did not have endometrial fluid se-
cretome available from subjects with endometriosis, which
would have made the analysis more robust.
Interestingly, the present data showed a trend of up-
regulation of STC1 mRNA in ESE versus PE or MSE in control
samples, in contrast to microarray results from an earlier
study (4) showing a trend of down-regulation of STC1
mRNA in ESE from endometriosis versus non-endometriosis
samples, which correlated to modest down-regulation in
another microarray study (28) but was different from the
up-regulation of STC1 in MSE in women with endometriosis
in the present study. It may be suggested that the increase in
STC1 mRNA expression in women with endometriosis is an
attempt to compensate the simultaneously low receptor
expression during MSE in women with endometriosis. These
differences could be explained by the fact that in the present
study we used samples from an entirely different cohort of pa-
tients, and our control subjects for this part of the study were
carefully selected to not have any uterine or endometrial pa-
thology. In addition, the samples used for mRNA analyses in
our study were entirely from subjects with severe endometri-
osis based on availability of tissue, which, while decreasing
heterogeneity of the current results, may explain the discrep-
ancy with earlier reports.Correlation between mRNA and Protein
Significant abundance of STC1 protein in the secretome of
receptive midsecretory endometrium from healthy fertile vol-
unteers is a strong indicator of its involvement in the critical
process of implantation. The changes in mRNA level from PE/
ESE to MSE were not significant, but there was a trend toward
up-regulation in control subjects. The discrepancy between
transcript and protein expression is not surprising, because
poor correlation between transcript level and the amount of
corresponding protein has been shown previously, specif-
ically in endometrial research (29–31). When analyzing
proteomics data in the endometrium from women with
versus without endometriosis, Stephens et al. (31) did not
find a correlation between changes in protein abundance
with the use of published transcriptome data, suggesting
that extensive post-translation control of gene expression oc-
curs in the tissue and is an important factor directly linked toVOL. 106 NO. 3 / SEPTEMBER 1, 2016the phenotype. Moreover, Fassbender et al. (29) did not find
differences in mRNA level in the secretory endometrium
from women with versus without endometriosis, although
proteomic analysis of the same samples allowed the diagnosis
of endometriosis with high sensitivity and specificity.STC1 Regulation via cAMP-dependent Protein
Kinase a Pathway
On the level of isolated pure human eSF, on the other hand,
STC1 was significantly and strongly up-regulated by cAMP,
but not by E2/P, in control subjects, suggesting that regulation
is likely mediated via the phosphokinase A (PKA) pathway.
In vitro, cAMP was shown to up-regulate STC1 gene expres-
sion in human mesenchymal stem cells and rat neuroblas-
toma cells (32, 33) but to down-regulate it in rat Sertoli and
Leydig cells (34). In the rodent male reproductive system,
the effect of cAMP on STC expression was mediated by
PKA pathway, because the phenotype could be rescued by
H89, a PKA-pathway inhibitor (34). In rat cortical neurons,
however, the cAMP effect was mediated through the ERK1/
2, not the PKA, pathway (35). In equine endometrium, STC1
was highly up-regulated in pregnant endometrium and ex-
pressed exclusively by endometrial glands, although it was
not significantly regulated by E2/P treatment of cultured
endometrial explants (36), the latter being in line with our
findings.STC1 as Possible New Marker of Decidualization
Some inconsistency between the MSE whole tissue STC1
quantitative RT-PCR and eSF decidualization results in the
present study could derive from differences in tissue cell
type composition. However, the PCR results in eSF culture ex-
periments supported to some degree the IHC results, with
higher STC1 eSF expression in control samples compared
with endometriosis. Dysregulation of STC1 in eutopic endo-
metrium and stromal cells from subjects with endometriosis
suggests its involvement in the pathogenesis of decidualiza-
tion defects. These observations lead us to suggest that
STC1 is potentially a new marker of decidualization, with
more studies needed to elaborate on this novel concept and
the roles of P signaling and the PKA pathway and other path-
ways in this regard.CASR in Human Endometrium
To the best of our knowledge, this is the first study reporting
on the expression of CASR in human endometrium. Calcium
homeostasis has been suggested to play a critical role in em-
bryo implantation in rodents and humans, because calcium
transporter genes are abundantly expressed in reproductive
tissues, including endometrium, in a cyclic manner, they are
regulated by ovarian steroid hormones, and their dysregula-
tion affects the expression of some important markers of
endometrial receptivity and decreases embryo implantation
(37, 38).
As mentioned, CASR, a known mediator of a wide range
of calcium-dependent physiologic responses in various tis-
sues, mediates STC1 transcription in response to extracellular689
ORIGINAL ARTICLE: ENDOMETRIOSIScalcium in fish and is induced in rat endometrium during im-
plantation and subsequent decidualization, particularly in
luminal and glandular epithelial cells (15). In the present
study, CASR did not exhibit variation in its mRNA expression
under cyclic hormone influence or in endometriosis t the tis-
sue level. In addition, we did not observe stromal expression
of CASR in the samples analyzed, in contrast to its high
expression in rat endometrium during implantation and de-
cidualization (15). In our study, absence of amplification of
the CASR transcript in eSF was confirmed by negative stromal
immunoexpression of CASR in all samples, in line with an
earlier study showing CASR expression in rat luminal epithe-
lium but not stroma (39). In addition, the CASR transcript was
not detected in any of the array studies reviewed. This pattern
of expression suggests paracrine actions of stromal cell–
derived STC1 on endometrial epithelial cells.
Strengths, Limitations, and Conclusion
The strengths of the current study include its novelty, obtain-
ing endometrial flushings and biopsies from well character-
ized subjects. The limitations are the descriptive nature of
the study and relatively small sample sizes.
Thus, we have reported on the pattern of STC1 and CASR
mRNA and protein expression in endometrial tissue and
endometrial stromal cells from women with and without
endometriosis. Whether STC1 affects endometrial steroido-
genesis, similarly to reports in ovarian tissue (40–42), is an
appealing question for future investigation.
Further characterization of STC1 expression and function
in human endometrium in pathologic conditions, such as un-
explained infertility, is ongoing, as well as the analysis of se-
cretome in women with unexplained infertility.
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SUPPLEMENTAL TABLE 1
Identified stanniocalcin-1 peptides.
Peptide sequence Protein
Uniprot
ID
Missed
cleavages Mass, Da
Observed
peptide
charges
Posterior
error
probability
of
identification
Andromeda
identification
score
Intensity,
Secr1
LHD2
Intensity,
Secr1
LHD8
Intensity
ratio,
LHD8/D2,
Secr1
Intensity,
Secr2
LHD2
Intensity,
Secr2
LHD7
IGPNMASLFHILQ
TDHCAQTHPR
STC1 P52823 0 2,643.280 3,4,5 3.33E187 161.68 0.0Eþ00 1.4Eþ07 NA 0.0Eþ00 1.4Eþ07
MIAEVQEECYSK STC1 P52823 0 1,485.648 2 7.47E07 96.745 0.0Eþ00 1.5Eþ06 NA 0.0Eþ00 9.6Eþ05
NLRGEEDSPSHIK STC1 P52823 1 1,480.727 3 1.26E06 92.939 1.8Eþ05 7.3Eþ05 4.0 0.0Eþ00 5.6Eþ05
NLRGEEDSPSHIKR STC1 P52823 2 1,636.828 3 2.60E03 60.55 0.0Eþ00 3.4Eþ05 NA 0.0Eþ00 1.4Eþ05
NPEAITEVVQLPNHFSNR STC1 P52823 0 2,064.039 2,3 4.86E181 176.69 0.0Eþ00 3.9Eþ06 NA 0.0Eþ00 1.8Eþ06
RNPEAITEVVQLPNHFSNR STC1 P52823 1 2,220.140 3,4 7.11E168 177.08 0.0Eþ00 1.2Eþ07 NA 0.0Eþ00 1.1Eþ07
SLLECDEDTVSTIR STC1 P52823 0 1,636.761 2,3 5.30E24 108.58 0.0Eþ00 7.1Eþ06 NA 0.0Eþ00 5.4Eþ06
VAAQNSAEVVR STC1 P52823 0 1,142.604 2 9.56E04 89.266 9.1Eþ05 1.2Eþ07 13.7 7.0Eþ05 7.5Eþ06
Intensity
ratio,
LHD8/
D2,
Secr2
Intensity,
Secr3
LHD2
Intensity,
Secr3
LHD9
Intensity
ratio,
LHD8/
D2,
Secr3
Intensity,
Secr4
LHD2
Intensity,
Secr4
LHD8
Intensity
ratio,
LHD8/
D2,
Secr4
Intensity,
Secr5
LHD2
Intensity,
Secr5
LHD8
Intensity
ratio,
LHD8/
D2,
Secr5
Intensity,
Secr6
LHD2
Intensity,
Secr6
LHD8
Intensity
ratio,
LHD8/
D2,
Secr6
IGPNMASLFHILQ
TDHCAQTHPR
NA 0.0Eþ00 5.1Eþ06 NA 6.3Eþ05 8.7Eþ07 137.1 0.0Eþ00 8.4Eþ06 NA 0.0Eþ00 3.1Eþ08 NA
MIAEVQEECYSK NA 0.0Eþ00 6.5Eþ05 NA 0.0Eþ00 5.6Eþ06 NA 0.0Eþ00 1.6Eþ06 NA 0.0Eþ00 6.8Eþ07 NA
NLRGEEDSPSHIK NA 0.0Eþ00 4.2Eþ05 NA 3.2Eþ05 2.9Eþ06 9.2 2.6Eþ05 5.3Eþ05 2.0 0.0Eþ00 3.6Eþ06 NA
NLRGEEDSPSHIKR NA 0.0Eþ00 0.0Eþ00 NA 0.0Eþ00 1.4Eþ06 NA 0.0Eþ00 3.1Eþ05 NA 0.0Eþ00 2.6Eþ06 NA
NPEAITEVVQLPNHFSNR NA 0.0Eþ00 0.0Eþ00 NA 0.0Eþ00 1.3Eþ07 NA 0.0Eþ00 1.3Eþ06 NA 0.0Eþ00 1.0Eþ08 NA
RNPEAITEVVQLPNHFSNR NA 6.7Eþ05 6.4Eþ06 9.5 0.0Eþ00 7.5Eþ07 NA 1.1Eþ06 1.4Eþ07 12.3 1.8Eþ06 3.1Eþ08 169.2
SLLECDEDTVSTIR NA 0.0Eþ00 3.8Eþ06 NA 0.0Eþ00 6.9Eþ07 NA 6.3Eþ05 3.4Eþ06 5.4 3.1Eþ06 2.2Eþ08 72.4
VAAQNSAEVVR 10.7 5.1Eþ05 5.2Eþ06 10.2 9.9Eþ05 5.7Eþ07 57.2 1.1Eþ06 1.3Eþ07 12.3 3.7Eþ06 2.1Eþ08 55.9
Note: Sequences along with peptide identification and quantification parameters are presented. Note that when the peptide signal had fallen below the limit of peak integration (limit of
quantification), the intensity values are presented as zeros.
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